NCT03787901 is a NA clinical trial of Morula Vitrification in Infertility, sponsored by Egyptian Foundation of Reproductive Endocrinology.

Who is sponsoring NCT03787901?

NCT03787901 is sponsored by Egyptian Foundation of Reproductive Endocrinology.

What drugs are being tested in NCT03787901?

Interventions in NCT03787901: Morula Vitrification.

What condition does NCT03787901 study?

NCT03787901 studies Infertility.

Is NCT03787901 still recruiting?

NCT03787901 is currently terminated. Last updated 14 June 2022.

Last reviewed 2022-06-14 · How we verify

NCT03787901

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparing the Ongoing Pregnancy Rate for Vitrification of Day-4 Morula With Day-5 Blast

Terminated NA Last updated 14 June 2022

What this trial tests

NA trial testing Morula Vitrification in Infertility in 53 participants. Terminated before completion.

Timeline

15 January 2019

Primary endpoint
31 May 2020

1 June 2020

Quick facts

Lead sponsor	Egyptian Foundation of Reproductive Endocrinology
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	other
Enrollment	53
Start date	15 January 2019
Primary completion	31 May 2020
Estimated completion	1 June 2020
Sites	4 locations across Egypt

Drugs / interventions tested

Morula Vitrification

Conditions studied

Infertility — all drugs for Infertility →

Sponsor

Egyptian Foundation of Reproductive Endocrinology

Who can join

Adults 18 to 40, female only, with Infertility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparing the vitrification at Day-4 (morula stage) with the blastocyst stage vitrification outcomes with the transfer of all day 5 after warming seems need evaluation. To the best of our knowledge, there has been no random-controlled trial conducted such comparison. Altogether, this trial is to evaluate the morula stage vitrification to blastocyst vitrification on the ongoing pregnancy rate after ICSI.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Infertility

Currently open trials in the same condition.

NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03787901 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Egyptian Foundation of Reproductive Endocrinology
Last refreshed: 14 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03787901.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing